Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025342 | 0.84 | BRS3 (0.34) | FDPSMEN1KMT2ANR3C1ADORA3 | |
| SCHEMBL13310648 | 0.80 | FPR2 (0.50) | FDPSMEN1KMT2AFPR2 | |
| SCHEMBL4077931 | 0.78 | MAPT (0.35) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL1106473 | 0.76 | ADORA2A (0.35) | NR3C1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL13439283 | 0.76 | ADORA3 (0.33) | NR3C1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL859290 | 0.76 | NR3C1 (0.33) | NR3C1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5654711 | 0.76 | ADORA3 (0.35) | FDPSMEN1KMT2ANR3C1ADORA3 | |
| SCHEMBL14254645 | 0.74 | KCNH2 (0.35) | KMT2AADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4404604 | 0.74 | FDPS (0.56) | FDPSMEN1KMT2A | |
| SCHEMBL23043665 | 0.73 | ADORA3 (0.36) | NR3C1ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | FDPS 2178/4885MEN1 2449/4885KMT2A 751/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | FDPS 2178/4885MEN1 2449/4885KMT2A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.